

# INDEX

For field names and large topics, the main reference page is underlined when multiple pages are listed.

Field names are shown in **boldface**.

## INDEX

180-day reporting rule.....	3
6-month reporting rule .....	3
abbreviations, address .....	56, 58, Appendix F
ablation, radiofrequency.....	178, 189, D-19, D-25, D-46
<b>Abstracted By</b> .....	46
<b>Accession Number</b> .....	8, 37
<b>Accession Number--Hosp (Accession Number)</b> .....	8, 37
<b>Addr at DX--City (City / Town at Diagnosis)</b> .....	57
<b>Addr at DX--No &amp; Street (Street Address at Diagnosis)</b> .....	54, 55-56
<b>Addr at Dx--Postal Code (ZIP / Postal Code at Diagnosis)</b> .....	59
<b>Addr at DX--State (State at Diagnosis)</b> .....	57-58
<b>Addr at DX--Supplementl (Street Address at Diagnosis--Supplemental</b> .....	54, 55, 56
<b>Addr Current--City</b> .....	59
<b>Addr Current--No &amp; Street</b> .....	59
<b>Addr Current--Postal Code</b> .....	59
<b>Addr Current--State</b> .....	59
<b>Addr Current--Supplementl</b> .....	59
address abbreviations .....	56, 58, Appendix F
Address at Diagnosis.....	8, 54-59
address, current .....	54, 55, 59
adenocarcinoma in adenomatous polyposis coli .....	18
adenocarcinoma in multiple (adenomatous) polyps.....	18
adrenalectomy & endocrine procedures.....	205
<b>AFP &amp; CS Site-Specific Factor 1</b> .....	168B, 168E
<b>Age at Diagnosis</b> .....	8, 51-52
AIN III & reportability.....	12, 13, 95
AIN III & sequence number.....	42
AJCC staging .....	123-143, 163
AJCC staging & timing rule.....	125
"aka" name .....	50
<b>Alias</b> .....	50
Allopurinol.....	197, 208
alpha-fetoprotein test & <b>CS Site-Specific Factor 1</b> .....	168B, 168E
alpha-fetoprotein test & <b>Diagnostic Confirmation</b> .....	121
"also known as" name .....	50
ambiguous terms, cancer diagnosis.....	13-14
anal intraepithelial neoplasia & reportability .....	12, 95
anal intraepithelial neoplasia & sequence number .....	42
analytic cases, reportability .....	2, 3

## INDEX

ancillary drugs.....	197, 208, 211
Angiostatin.....	207
anus & "site difference".....	16
"apparently" & cancer diagnosis.....	14
"appears" & cancer diagnosis.....	14
Aredia.....	197, 208
aspiration, bone marrow & <b>Diagnostic Confirmation</b> .....	121
aspiration of cells, fine needle & <b>Diagnostic Confirmation</b> .....	121
aspirin.....	208
astrocytomas, pilocytic & <b>Behavior Code</b> .....	11, 34, 95, 96
aTNM.....	126, 127
at-this-facility treatment fields (general instructions).....	171
autopsy & AJCC staging.....	126, 127
autopsy & <b>Diagnostic Confirmation</b> .....	121, 122
autopsy-only case & <b>Date of Diagnosis</b> .....	109
autopsy-only case & <b>Date of First Contact</b> .....	46
autopsy-only case & reportability.....	2, 3, <u>7-8</u>
autopsy-only case & treatment start dates.....	172
"autumn" & date estimating.....	46, 110, 172
basal cell carcinoma of skin & reportability exceptions.....	11, 95
basal cell carcinoma of skin & sequence number.....	40, 41
BCG.....	202, D-47
beam radiation.....	189
<b>Behavior (92-00) ICD-O-2</b> .....	8, <u>94</u>
<b>Behavior Code ICD-O-3</b> .....	8, <u>95-98</u>
behavior <i>in situ</i> , terminology.....	97-98
behavior narrative.....	109
behavior transformation & single-vs.-multiple primaries.....	26
benign behavior & reportability.....	11
benign CNS tumors & diagnostic terms.....	13-14
benign CNS tumors & sequence number.....	40, 42-43
benign tumors & grade code.....	104
Bexxar.....	191, 203, 206B
bilateral cancers & single-vs.-multiple primaries.....	23
biological response modifier therapy.....	202-204
biopsy & <b>Diagnostic Confirmation</b> .....	121
biopsy, fine needle & <b>Diagnostic Confirmation</b> .....	121
biopsy, needle & surgical diagnostic/staging procedures.....	175
biopsy, negative.....	35
biopsy, positive, first date of.....	177
<b>Birth Date</b> .....	8, <u>50-51</u>
<b>Birthplace</b> .....	52-53, Appendix A

## INDEX

birthplace text.....	215
bladder cancers & immunotherapy .....	202, D-47
bladder cancers & <b>Primary Site Code</b> .....	81C-81D
bladder cancers & single-vs.-multiple primaries .....	21, 22
blood smear, peripheral, & <b>Diagnostic Confirmation</b> .....	121, 122
blood transfusion.....	208, 209
Bloom-Richardson grade .....	106-107
bone & "site difference" .....	16
bone marrow aspiration & <b>Diagnostic Confirmation</b> .....	121
bone marrow transplants .....	205-206
Book 8 drugs vs. SEER*Rx database .....	206B
books, reference .....	4-7
boost radiation.....	190
borderline behavior & reportability .....	11
borderline behavior tumors & grade code.....	104
borderline CNS tumors & diagnostic terms .....	13-14
borderline CNS tumors & sequence number .....	40, 42-43
brachytherapy.....	189, 190
brain & "site difference" .....	16
brain tumors & diagnostic terms .....	13-14
brain tumors & grade code.....	104
brain tumors & "histologic type difference" .....	19
brain tumors & <b>Laterality</b> .....	82
brain tumors & <b>Regional Nodes Examined</b> .....	153
brain tumors & <b>Regional Nodes Positive</b> .....	156
brain tumors & reportability .....	11
brain tumors & scope of regional lymph node surgery.....	183
brain tumors & sequence number .....	40, 42-43
brain tumors & single-vs.-multiple primaries .....	16-21, 23, 25-26
brain tumors & surgery of other sites.....	185
breast cancers & grade .....	106-107
breast cancers & <b>Primary Site Code</b> .....	81A-81B
breast cancers & single-vs.-multiple primaries.....	22, 24, 25
breast duct and lobular carcinomas & histology .....	92
breast duct and lobular carcinomas & primary site.....	79
BRM therapy.....	202-204
CA-125 & <b>CS Site-Specific Factor 1</b> .....	168D
cancer history & reportability .....	15
"cannot be ruled out" & cancer diagnosis .....	14
carbohydrate antigen 125 & <b>CS Site-Specific Factor 1</b> .....	168D
carcinoembryonic antigen & <b>CS Site-Specific Factor 1</b> .....	168B
carcinoma <i>in situ</i> of the uterine cervix & reportability .....	12, 96

## INDEX

carcinomas of skin & reportability exceptions.....	11, 95
carcinomas, ductal & single-vs.-multiple primaries.....	22, 24, 25
carcinomas, follicular & papillary.....	22
carcinomas, lobular & single-vs.-multiple primaries.....	22, 24
carcinomas, papillary & follicular.....	22
casefinding sources .....	2
CD, reporting on .....	3
<b>CEA &amp; CS Site-Specific Factor 1</b> .....	168B
cell lineage of lymphomas/leukemias & grade code.....	100-108
cervical carcinoma <i>in situ</i> & reportability.....	12, 96
cervical intraepithelial neoplasia & reportability.....	12, 96
changes to submitted data .....	3-4
chemoembolization & Chemotherapy.....	195, 207, D-20
chemoembolization & Surgery .....	178, 195, 207, D-20
chemotherapy .....	195-199
<b>Chemotherapy -- At This Facility</b> .....	199
chemotherapy & chemoembolization .....	195, 207
<b>Chemotherapy -- Date Started</b> .....	199
<b>Chemotherapy -- Narrative</b> .....	199
<b>Chemotherapy -- Summary</b> .....	199
chemotherapy, text .....	199
cigarette use .....	72
CIMS-Satellite system .....	3, 8, 213, 215, 217
CIN III & reportability .....	12, 96
<b>City / Town at Diagnosis</b> .....	57
<b>City / Town -- Current</b> .....	59
Class 0 case & 2006 COC changes .....	35
Class 3 case, reportability .....	2, 3, <u>7-8</u> , 111, 112
Class 4 case, reportability .....	2, 3, <u>7-8</u>
Class 5 case & AJCC staging.....	126, 127
Class 5 case & <b>Date of Diagnosis</b> .....	109
Class 5 case & <b>Date of First Contact</b> .....	46
Class 5 case & reportability .....	2, 3, <u>7-8</u>
Class 5 case & treatment start dates .....	172, 173
Class 6 case & reportability .....	2, 3, <u>7-8</u> , 111, 112
Class 7 case & <b>Date of Diagnosis</b> .....	110
Class 7 case & <b>Date of First Contact</b> .....	46
Class 7 case & reportability .....	2, 3, <u>7-8</u> , 35, 111, 113
Class 9 case & reportability .....	2, 3, <u>7-8</u>
<b>Class of Case</b> .....	111-113
<b>Clinical Descriptor</b> .....	<u>127</u> , 163
<b>Clinical M</b> .....	<u>132-133</u> , 163

## INDEX

<b>Clinical N</b> .....	<u>130-131</u> , 163
<b>Clinical Stage Grouping</b> .....	<u>133-134</u> , 163
<b>Clinical T</b> .....	<u>128-130</u> , 163
Clonidine .....	197
CNS & "site difference" .....	16
CNS tumors & diagnostic terms .....	13-14
CNS tumors & grade code .....	104
CNS tumors & "histologic type difference" .....	19
CNS tumors & <b>Laterality</b> .....	82
CNS tumors & <b>Regional Nodes Examined</b> .....	153
CNS tumors & <b>Regional Nodes Positive</b> .....	156
CNS tumors & reportability .....	11
CNS tumors & scope of regional lymph node surgery .....	183
CNS tumors & sequence number .....	40, 42-43
CNS tumors & single-vs.-multiple primaries .....	16-21, 23, 25-26
CNS tumors & surgery of other sites .....	185
CNS tumors & WHO grade .....	104
<b>COC Coding System -- Current</b> .....	219
<b>COC Coding System -- Original</b> .....	219
<b>Coding System for EOD</b> .....	219
coding system, morphology .....	218
collaborative staging .....	162-168E
colon & "site difference" .....	16, 18
colon cancers & single-vs.-multiple primaries .....	16, 18, 22
combination codes, morphology .....	5, 24, 25, 29, <u>90-94</u>
<b>Comments / Narrative Remarks</b> .....	215
<b>Comments/Narrative Remarks</b> & address .....	54, 55, 59, 215
<b>Comments/Narrative Remarks</b> & <b>Age at Diagnosis</b> .....	52, 215
<b>Comments/Narrative Remarks</b> & cancer history .....	44, 215
<b>Comments/Narrative Remarks</b> & estimated date .....	50, 110, 215
<b>Comments/Narrative Remarks</b> & foreign country name .....	57, 215
<b>Comments/Narrative Remarks</b> & gender/name .....	60, 215
<b>Comments/Narrative Remarks</b> & homeless patients .....	55
<b>Comments/Narrative Remarks</b> & morphology .....	81, 86, 109, 215
<b>Comments/Narrative Remarks</b> & primary site .....	81, 86, 109, 215
compact disk, reporting on .....	3
"comparable with" & cancer diagnosis .....	14
"compatible with" & cancer diagnosis .....	14
completed, case (date on which completed) .....	217
complex morphologies .....	5, <u>90-94</u>
confidential patient information .....	<u>1-2</u> , 158, 215
confirmation, diagnostic codes .....	121-122

## INDEX

confirmation, pathologic & reportability .....	13
connective tissue & "site difference" .....	16
"consistent with" & cancer diagnosis.....	14
consultation-only cases & reportability .....	35
conversion flag, ICD-O-2 .....	99
conversion flag, ICD-O-3 .....	99
"couple years" & date estimates.....	110
craniopharyngeal duct & reportability .....	11, 13
craniopharyngeal duct & sequence number .....	40, 42-43
craniopharyngeal duct & "site difference" .....	16, 17
cross-indexed lymphomas/leukemias.....	79, <u>88-89</u>
<b>CS Extension</b> .....	165
<b>CS Lymph Nodes</b> .....	166
<b>CS Mets at DX</b> .....	166
<b>CS Mets Eval</b> .....	166
<b>CS Reg Nodes Eval</b> .....	166
<b>CS Site-Specific Factor 1 - 6</b> .....	<u>167-168E</u>
<b>CS Tumor Size</b> .....	163, <u>165</u>
<b>CS Tumor Size/Ext Eval</b> .....	165
<b>CS Version 1st</b> .....	165
Current Address .....	8, 54, 55, <u>59</u>
current COC coding .....	219
current coding, morphology .....	218
current treatment, coding system .....	219
cytogenetic data & ICD-O-3 histologic type .....	87
cytology & <b>Diagnostic Confirmation</b> .....	121
cytology, positive .....	35
cytology, "suspicious".....	14, 35
<b>Date Case Completed</b> .....	217
<b>Date Case Report Exported</b> .....	217
<b>Date Case Report Received</b> .....	217
date, chemotherapy .....	199
date estimating .....	i, 46, 50, 110, 172, 173, 199, 202, 204, 213, 215
date exported (case) .....	217
date, hormone therapy.....	202
date, immunotherapy.....	204
<b>Date of 1st Contact (Date of First Contact)</b> .....	i, 3, <u>46-47</u>
<b>Date of 1st Crs RX--COC</b> .....	173
<b>Date of 1st Positive Bx</b> .....	177
date of birth .....	8, <u>50-51</u>
date of death.....	214
<b>Date of Diagnosis</b> .....	i, 3, 8, <u>109-110</u>

## INDEX

<b>Date of Diagnosis</b> for reportable recurrence .....	9
<b>Date of First Contact</b> .....	i, 3, <u>46-47</u>
Date of First Positive Biopsy ( <b>Date of 1st Positive Bx</b> ).....	177
<b>Date of First Recurrence</b> .....	9, <u>213</u>
<b>Date of First-Course Treatment--COC</b> .....	173
<b>Date of Last Contact</b> .....	8, <u>214</u>
<b>Date of Most Definitive Resection</b> .....	181
date, other therapy .....	210
date, radiation.....	193
date, reference, MCR .....	1, 2
date, surgery .....	180
date, surgical diagnostic/staging procedures .....	177
date, systemic therapy .....	194
dates, treatment .....	171, <u>172</u>
death certificate-only case & <b>Date of First Contact</b> .....	47
death certificate-only case & treatment start dates .....	172
death, date .....	214
death, place .....	214, Appendix A
Decadron .....	197, 200
"default primary site" in ICD-O-3.....	78
deleting submitted data .....	3-4
derived Collaborative Staging field storage codes & display strings .....	167, 168
descriptor, clinical.....	<u>127</u> , 163
descriptor, pathologic.....	<u>134-135</u> , 163
Dexamethasone .....	197
<b>Diagnostic Confirmation</b> codes .....	121-122
diagnostic/staging procedures, surgical .....	174-177
diagnostic terms .....	13-14
differentiation code .....	8, <u>100-108</u>
differentiation-inducing agents .....	197, 208
dilation and curettage & <b>Diagnostic Confirmation</b> .....	121
dilation and curettage & surgical diagnostic/staging procedures.....	175
diskette labeling .....	37, 39
diskette, reporting on.....	3
drugs, ancillary.....	197, 208, 211
drugs, differences between Book 8 and SEER*Rx.....	206B
drugs, differentiation-inducing.....	197, 208
duct and lobular carcinomas & histology.....	92
duct and lobular carcinomas & primary site .....	79
ductal carcinomas, breast & single-vs.-multiple primaries .....	22, 24, 25
dysplasia, high-grade & reportability.....	14



## INDEX

dysplasia, severe & reportability.....	14
"early in year" & date estimates.....	46, 110
embolization.....	207, D-20
employment.....	73-75
endocrine procedures .....	205-206
endocrine radiation.....	205-206
endocrine surgery.....	205-206
endoscopies, text.....	159
Endostatin .....	207
EOD coding system, codes .....	219
<b>EOD -- Extension Prostate Pathology</b> .....	157
<b>EOD -- Extension</b> .....	157
<b>EOD -- Lymph Node Involvement</b> .....	157
<b>EOD -- Tumor Size</b> .....	<u>116-121</u> , 163
Epogen .....	197, 203, 208
"equivocal" & cancer diagnosis .....	14
<b>ERA &amp; CS Site-Specific Factor 1</b> .....	168C
estimating a date.....	i, 46, 50, 110, 172, 173, 199, 202, 204, 213, 215
estrogen receptor assay & <b>CS Site-Specific Factor 1</b> .....	168C
exported, case (date on which exported).....	217
eye cancers & single-vs.-multiple primaries .....	23
facility codes .....	37, <u>38</u> , 114, 115, Appendix G
Facility Identification Number (FIN).....	37, <u>38</u> , 114, 115, Appendix G
<b>Facility Name</b> .....	37
"fall" & date estimating.....	46, 110, 172
familial polyposis .....	18, 79, 119, 120
"favors" & cancer diagnosis.....	14
"few years" and date estimates.....	110
FIN .....	37, <u>38</u> , 39, 114, 115, <u>Appendix G</u>
fine needle aspiration .....	175
first course of treatment, definition.....	169-170
first course of treatment & leukemias .....	170
<b>First Name</b> , patient.....	8, <u>49</u>
first recurrence .....	8-10, 15, 21, 24, <u>213</u> , 218
fluids & <b>Diagnostic Confirmation</b> .....	121
<b>Following Physician Name</b> .....	47
FNA (fine needle aspiration).....	175
free care code .....	45
Fuhrman Grade .....	102, <u>107</u>
G-CSF .....	208
gender codes.....	8, <u>60</u>
germ cell tumors & histologic type.....	93

## INDEX

Gleason Pattern & grade .....	107-108
Gleason Score & grade .....	107-108
Gleevec .....	203
Gliadel wafer.....	195
<b>Grade / Differentiation / Immunophenotype Code</b> .....	8, <u>100-108</u>
grade narrative.....	109
grade, nuclear .....	<u>102</u> , 106, 107
HCG & CS Site-Specific Factor 2.....	168E
<b>Hematologic Transplants &amp; Endocrine Procedures</b> .....	205-206
hematopoietic diseases & <b>EOD -- Tumor Size</b> .....	119, 120
hematopoietic diseases & "histologic type difference" .....	19, <u>27-33</u>
hematopoietic diseases & other therapy.....	208-209
hematopoietic diseases & <b>Regional Nodes Examined</b> .....	153
hematopoietic diseases & <b>Regional Nodes Positive</b> .....	156
hematopoietic diseases & scope of regional lymph node surgery .....	183
hematopoietic diseases & single-vs.-multiple primaries.....	19, <u>27-33</u>
hematopoietic diseases & surgery of other sites .....	185
Herceptin.....	202, 206B
"high-grade" .....	14, 100, 102, 103, <u>104</u> , 106, <u>107</u>
high-grade dysplasia & grade code .....	102, 103
high-grade dysplasia & reportability.....	14
Hispanic origin.....	68-72
"histologic type difference" .....	19
<b>Histologic Type ICD-O-3</b> .....	8, <u>87-94</u>
<b>Histology (92-00) ICD-O-2 (ICD-O-2 Histologic Type Code)</b> .....	8, <u>87</u>
histology code, ICD-O-2.....	8, <u>87</u>
histology narrative.....	109
histology/behavior/grade narrative & unusual primary site.....	86, 109
history and physical examination text.....	158
history, cancers identified by, & reportability .....	12, 15
HMO code.....	45
hormone replacement therapy .....	200
hormone text .....	<u>202</u> , 205
hormone therapy .....	200-202
<b>Hormone Therapy -- At This Facility</b> .....	201
<b>Hormone Therapy -- Date Started</b> .....	202
<b>Hormone Therapy -- Narrative</b> .....	202
<b>Hormone Therapy -- Summary</b> .....	201
hospital codes.....	37, <u>38</u> , 114, 115, Appendix G
hospital Sequence Number.....	8, 9, <u>39-44</u>
human chorionic gonadotropin & <b>CS Site-Specific Factor 2</b> .....	168E

## INDEX

hyperbaric oxygen.....	207
hypophysectomy & endocrine procedures .....	205
ICD-O-1 primary site .....	16-17
<b>ICD-O-2 Behavior Code</b> .....	8, <u>94</u>
<b>ICD-O-2 Conversion Flag</b> .....	99
<b>ICD-O-2 Histologic Type Code</b> .....	8, <u>87</u>
ICD-O-2 & reportability .....	34
<b>ICD-O-3 Behavior Code</b> .....	8, <u>95-98</u>
<b>ICD-O-3 Conversion Flag</b> .....	99
<b>ICD-O-3 Histologic Type Code</b> .....	8, <u>87-94</u>
ICD-O-3 & reportability .....	34
ill-defined primary .....	<u>78-79</u> , 81
ill-defined primary & <b>EOD -- Tumor Size</b> .....	119, 120
ill-defined primary & <b>Regional Nodes Examined</b> .....	153
ill-defined primary & <b>Regional Nodes Positive</b> .....	156
ill-defined primary & scope of regional lymph node surgery .....	183
ill-defined primary & surgery of other sites.....	185
immunoglobulin, iodine-labeled & Radiation.....	189, 203
immunohistochemical tests & pM .....	140
immunohistochemical tests & pN .....	138
immunophenotype code .....	8, <u>100-108</u>
immunoproliferative diseases & <b>EOD -- Tumor Size</b> .....	119, 120
immunoproliferative diseases & <b>Regional Nodes Examined</b> .....	153
immunoproliferative diseases & <b>Regional Nodes Positive</b> .....	156
immunoproliferative diseases & scope of regional lymph node surgery .....	183
immunoproliferative diseases & surgery of other sites.....	185
immunotherapy .....	202-204
<b>Immunotherapy -- At This Facility</b> .....	204
immunotherapy & bladder cancers .....	202, D-47
<b>Immunotherapy -- Date Started</b> .....	204
immunotherapy & iodine-labeled immunoglobulin.....	189, 203
<b>Immunotherapy -- Narrative</b> .....	204
<b>Immunotherapy -- Summary</b> .....	204
immunotherapy text .....	<u>204</u> , 205
<i>in situ</i> behavior terms.....	97-98
<i>in situ</i> Summary Stage terms .....	148
<i>in situ</i> tumors & grade code .....	102
<i>in situ</i> tumors & Summary Stage .....	148
industry and occupation .....	73-75
"infra" & primary site .....	81
<b>Institution Referred From</b> .....	114

## INDEX

<b>Institution Referred To</b> .....	115
insurance codes .....	45
"intermediate grade" .....	103, <u>104</u> , 106, <u>107</u>
intracranial tumors & diagnostic terms .....	13-14
intracranial tumors & "histologic type difference" .....	19
intracranial tumors & <b>Laterality</b> .....	82
intracranial tumors & reportability.....	11
intracranial tumors & sequence number .....	40, 42-43
intracranial tumors & single-vs.-multiple primaries .....	16-21, 23, 25-26
intraepithelial neoplasia, anal & reportability .....	12, 95
intraepithelial neoplasia, anal & sequence number.....	42
intraepithelial neoplasia, cervical & reportability .....	12, 96
intraepithelial neoplasia, prostate & reportability .....	12, 96
intraepithelial neoplasia, prostate & single-vs.-multiple primaries.....	21
intraepithelial neoplasia, vaginal & reportability.....	12, 95
intraepithelial neoplasia, vaginal & sequence number.....	42
intraepithelial neoplasia, vulvar & reportability .....	12, 95
intraepithelial neoplasia, vulvar & sequence number .....	42
iodine-labeled immunoglobulin .....	189, 203
Iressa .....	202
isolated tumor cells, lymph node .....	138, 140
"JR" <b>Name Suffix</b> .....	48
Kaposi sarcoma & primary site.....	79
Kaposi sarcoma & single-vs.-multiple primaries.....	20, 21, 25
kidney cancers & grade.....	107
kidney cancers & single-vs.-multiple primaries.....	23
L-Asparaginase .....	196, 203
laboratory tests, text .....	160
laboratory tests & Collaborative Staging fields .....	168A-168E
lactate dehydrogenase & <b>CS Site-Specific Factor 3</b> .....	168E
lactate dehydrogenase & <b>CS Site-Specific Factor 4</b> .....	168B
last contact, date.....	8, <u>214</u>
<b>Last Name</b> , patient .....	8, <u>48</u>
"late in year" & date estimates .....	46, 110
<b>Laterality</b> .....	8, <u>82-85</u>
laterality & single-vs.-multiple primaries .....	23
Latino origin.....	68-72
LCIS & reportability .....	14
LDH & <b>CS Site-Specific Factor 3</b> .....	168E
LDH & <b>CS Site-Specific Factor 4</b> .....	168B
legislation, MCR .....	1
Letterer-Siwe disease & <b>EOD -- Tumor Size</b> .....	119, 120

## INDEX

Letterer-Siwe disease & <b>Regional Nodes Examined</b> .....	153
Letterer-Siwe disease & <b>Regional Nodes Positive</b> .....	156
Leucovorin .....	197, 208
leukemias & ancillary drugs & Hormone Therapy .....	197, 200
leukemias & first course of treatment .....	170
leukemias & "histologic type difference" .....	19, 27-33
leukemias & primary site .....	79
leukemias & single-vs.-multiple primaries .....	19, 27-33
leukemias & lymphomas, cross-indexed.....	79, <u>88-89</u>
leukemias & lymphomas & grade code .....	100-108
leukemic reticuloendotheliosis & primary site .....	79
liver cancers & <b>Diagnostic Confirmation</b> .....	121
lobular and duct carcinomas & histology.....	92
lobular and duct carcinomas & primary site .....	79
lobular carcinoma & reportability .....	14
lobular carcinomas, breast & single-vs.-multiple primaries .....	22, 24
lobular neoplasia & behavior .....	97
"low-grade" .....	100, 103, <u>104</u> , 106, <u>107</u>
lung cancers & Summary Stage 2000 .....	150
lymph node surgery, regional.....	182-185
lymphomas & ancillary drugs & Hormone Therapy.....	197, 200
lymphomas & <b>EOD -- Tumor Size</b> .....	119
lymphomas & "histologic type difference" .....	19, 27-33
lymphomas & primary site.....	77, <u>80</u>
lymphomas & primary site surgery .....	178
lymphomas & scope of regional lymph node surgery.....	183
lymphomas & single-vs.-multiple primaries .....	19, 27-33
lymphomas & Summary Stage 2000.....	145, 150
lymphomas/leukemias & grade code .....	100-108
lymphomas/leukemias, cross-indexed.....	79, <u>88-89</u>
lymphoreticular process & primary site.....	80
M, clinical .....	<u>132-133</u> , 163
M, pathologic .....	<u>139-141</u> , 163
"M"-type NAACCR records .....	4, 9, 218
<b>Maiden Name</b> .....	49
malignant transformation & single-vs.-multiple primaries .....	26
manuals, reference .....	4-7
<b>Marital Status at Diagnosis</b> .....	60
marital status text .....	215
Marmistat .....	207
marriage codes .....	60
MCR case reportability .....	2, 7-10, <u>11-35</u> , 95-96, 111-113

## INDEX

MCR legislation .....	1
MCR reference date .....	1, 2
MCR regulations .....	1, 2
MCR reportability & <b>Behavior Code</b> .....	8, <u>95-96</u>
Medicaid code .....	45
<b>Medical Record Number</b> .....	8, <u>39</u>
Medicare claim number .....	53
Medicare code .....	45
melanomas & <b>EOD -- Tumor Size</b> .....	116, 121
melanomas & primary site .....	80
melanomas & single-vs.-multiple primaries .....	16, 25
melanomas & "site difference" .....	16
meninges & "site difference" .....	16
microinvasion.....	98, 148
micrometastases, lymph node .....	138, 140
<b>Middle Name</b> , patient.....	8, <u>49</u>
mixed behaviors & grade code.....	102
mixed germ cell tumors & histologic type.....	93
mixed morphologies.....	90-93
modifications to submitted data .....	3-4
molecular tests & pM.....	140
molecular tests & pN.....	138
monoclonal antibodies .....	191, 203, 206B
<b>Morph Coding Sys--Current</b> .....	218
<b>Morph Coding Sys--Originl</b> .....	218
morphologies, complex.....	90-93
morphologies, mixed.....	90-93
morphologies, multiple .....	90-93
morphologies, site-associated .....	78
<b>Morphology Coding System -- Current</b> .....	218
<b>Morphology Coding System -- Original</b> .....	218
morphology combination codes .....	5, 24, 25, 29, <u>90-94</u>
"most likely" & cancer diagnosis.....	14
multiple behaviors & grade code .....	102
multiple histologic types .....	90-93
multiple polyps, adenocarcinoma .....	18
multiple primaries rules .....	15-33
mycosis fungoides & primary site.....	80
myeloid sarcoma & primary site.....	79, 89
myelomas & ancillary drugs & Hormone Therapy .....	197, 200
myelomas & <b>Diagnostic Confirmation</b> .....	121
myelomas & <b>EOD -- Tumor Size</b> .....	119, 120

## INDEX

myelomas & <b>Regional Nodes Examined</b> .....	153
myelomas & <b>Regional Nodes Positive</b> .....	156
myeloproliferative diseases & <b>EOD -- Tumor Size</b> .....	119, 120
myeloproliferative diseases & <b>Regional Nodes Examined</b> .....	153
myeloproliferative diseases & <b>Regional Nodes Positive</b> .....	156
myeloproliferative diseases & scope of regional lymph node surgery .....	183
myeloproliferative diseases & surgery of other sites .....	185
N, clinical .....	<u>130-131</u> , 163
N, pathologic.....	<u>138-139</u> , 163
NAACCR layout version code.....	218
<b>NAACCR Record Version</b> .....	218
NAACCR Version 10 .....	i, 3
NAACCR Version 10.1 .....	i, 3
NAACCR version code.....	218
<b>Name--Alias (Alias)</b> .....	50
<b>Name--First (First Name)</b> .....	49
<b>Name--Last (Last Name)</b> .....	48
<b>Name--Maiden (Maiden Name)</b> .....	49
<b>Name--Middle (Middle Name)</b> .....	49
name of following physician.....	47
name of reporting facility.....	37
name of software vendor.....	217
name of vendor .....	217
<b>Name--Spouse/Parent</b> .....	76
<b>Name--Suffix</b> .....	48
<b>Name Suffix, patient</b> .....	48
narrative chemotherapy .....	199
narrative endoscopies.....	159
<b>Narrative Histology / Behavior / Grade</b> .....	109
<b>Narrative Histology/Behavior/Grade &amp; unusual</b> primary site .....	86, 109
narrative immunotherapy .....	<u>204</u> , 205
narrative lab tests .....	160
narrative operative.....	160
narrative other therapy .....	210
narrative pathology .....	161
narrative physical examination and patient history.....	158
<b>Narrative Primary Site</b> .....	86
<b>Narrative Primary Site &amp; Laterality</b> .....	83, 86
<b>Narrative Primary Site &amp; multiple tumors in primary site</b> .....	128
narrative radiation .....	193

## INDEX

narrative remarks.....	215
narrative remarks & address .....	54, 55, 59
narrative remarks & <b>Age at Diagnosis</b> .....	52
narrative remarks & an estimated date.....	50, 110, 215
narrative remarks & cancer history .....	44
narrative remarks & foreign country name .....	57
narrative remarks & gender/name.....	60
narrative remarks & homeless patients .....	55
narrative remarks & morphology .....	81, 86, 109
narrative remarks & primary site .....	81, 86, 109
narrative staging.....	161-162
narrative surgery .....	181
narrative surgery & surgical diagnostic/staging procedures .....	176, 177
narrative treatment & estimated start date (general instruction).....	172
narrative treatment fields .....	172
narrative X-rays and scans .....	159
narratives, staging .....	157-162
narratives, staging & lymphomas.....	134, 142
narratives, staging & multiple tumors in primary site.....	128, 135
narratives, staging & sites of metastasis .....	132, 140
narratives, staging & stage-related risk factors .....	133, 141
needle biopsies & surgical diagnostic/staging procedures.....	175
negative biopsy .....	35
neoadjuvant therapy & AJCC staging.....	125
neoadjuvant therapy & <b>EOD -- Tumor Size</b> .....	117
neoadjuvant therapy & <b>Regional Nodes Examined</b> .....	153
neoadjuvant therapy & <b>Regional Nodes Positive</b> .....	155
"neoplasm" & cancer diagnosis .....	14
nephroblastomas & single-vs.-multiple primaries .....	23
nerves & "site difference" .....	16
Neupogen .....	197, 203, 208
neuroblastomas & primary site .....	80
nonanalytic cases, reportability.....	2, 3, <u>7-8</u> , 111, 112, 113
non-diagnostic terms .....	13-14
non-malignant tumors & diagnostic terms.....	13-14
non-malignant tumors & "histologic type difference" .....	19
non-malignant tumors & reportability .....	11
non-malignant tumors & sequence number .....	40, 42-43
non-malignant tumors & single-vs.-multiple primaries.....	16-21, 23, 25-26
non-malignant tumors & "site difference" .....	16, 17
Nottingham (Bloom-Richardson) grade.....	106-107



## INDEX

<b>NPI--Inst Referred From</b> .....	114
<b>NPI--Inst Referred To</b> .....	114
<b>NPI--Physician--Follow-Up</b> .....	47
<b>NPI--Registry ID</b> .....	39
<b>NPI--Reporting Facility</b> .....	37
nuclear grade .....	<u>102</u> , 106, <u>107</u>
occupation and industry .....	73-75
oophorectomy & endocrine procedures .....	205
operative text.....	160
orchiectomy & endocrine procedures .....	205
original COC codes .....	219
original coding, morphology .....	218
other site surgery .....	185-186
other therapy .....	207-210
<b>Other Therapy -- At This Facility</b> .....	210
<b>Other Therapy -- Date Started</b> .....	210
<b>Other Therapy -- Narrative</b> .....	210
<b>Other Therapy -- Summary</b> .....	210
other therapy, text .....	210
other treatment .....	207-210
ovarian cancers & single-vs.-multiple primaries .....	23
oxygen, hyperbaric .....	207
Paget disease & behavior .....	98
Paget disease & single-vs.-multiple primaries .....	25
paired primary sites & <b>Laterality</b> .....	82-85
paired primary sites & single-vs.-multiple primaries.....	23
palliative care .....	169, 170-171, 173, 208, <u>210-211</u>
<b>Palliative Care -- At This Facility</b> .....	211
<b>Palliative Care &amp; Date of First Contact</b> .....	46
<b>Palliative Care -- Summary</b> .....	211
palliative procedures .....	210-211
paper, reporting on .....	3
papillary and follicular carcinomas .....	22
papillary carcinomas & reportability exceptions .....	11, 95
"para" & primary site .....	81
parent name .....	76
pathologic confirmation & reportability .....	13
<b>Pathologic Descriptor</b> .....	<u>134-135</u> , 163
<b>Pathologic M</b> .....	<u>139-141</u> , 163
<b>Pathologic N</b> .....	<u>138-139</u> , 163
<b>Pathologic Stage Grouping</b> .....	<u>141-142</u> , 163
<b>Pathologic T</b> .....	<u>135-137</u> , 163

## INDEX

pathology-only case & <b>Date of Diagnosis</b> .....	110
pathology-only case & <b>Date of First Contact</b> .....	46
pathology-only cases & reportability .....	35
pathology text.....	161
<b>Patient System ID-Hosp</b> .....	76
patient name .....	8, <u>48-50</u>
pediatric cases & AJCC staging.....	124
Pentostatin.....	196, 203
"peri" & primary site.....	81
phlebotomy .....	208
physical examination and patient history text.....	158
physician name.....	47
<b>Physician--Follow-Up</b> & text equivalent.....	47
physician office contact & <b>Date of First Contact</b> .....	46
physician offices & at-this-facility treatment (general instructions).....	171
pilocytic astrocytomas & <b>Behavior Code</b> .....	11, 34, 95, 96
PIN III & recurrences.....	21
PIN III & reportability .....	12, 96
PIN III & single-vs.-multiple primaries .....	21
pineal gland & reportability .....	11, 13
pineal gland & sequence number .....	40, 42-43
pineal gland & "site difference" .....	16, 17
pituitary gland & reportability .....	11, 13
pituitary gland & sequence number .....	40, 42-43
pituitary gland & "site difference" .....	16, 17
place of birth .....	52-53, Appendix A
<b>Place of Death</b> .....	<u>214</u> , Appendix A
placebo & clinical trial.....	207
positive cytology .....	35
"possible" & cancer diagnosis.....	14
Postal Code at diagnosis .....	59
Postal Code, current .....	59
"potentially" & cancer diagnosis.....	14
PPO code.....	45
<b>PRA &amp; CS Site-Specific Factor 2</b> .....	168C
"pre" & primary site.....	81
Prednisolone.....	197
Prednisone.....	197, 200
"presumed" & cancer diagnosis .....	14
<b>Primary Payer at Diagnosis</b> .....	45
<b>Primary Site Code</b> .....	8, <u>77-81</u>

## INDEX

primary site & cross-indexed lymphomas/leukemias .....	79, <u>88-89</u>
primary site narrative .....	86
primary site narrative & <b>Laterality</b> .....	83, 86
primary site narrative & multiple tumors in primary site.....	128
primary site & reportable recurrences.....	15
primary site surgery .....	178-180, 181, <u>Appendix D</u>
primary site surgery & lymphomas.....	178
primary sites, ICD-O-1 .....	16-17
"probable" & cancer diagnosis.....	14
Procrit.....	197, 203, 208
progesterone receptor assay & <b>CS Site-Specific Factor 2</b> .....	168C
prophylactic radiation .....	189, 190
prostate adenocarcinomas & single-vs.-multiple primaries .....	21
prostate cancers & <b>Diagnostic Confirmation</b> .....	121
prostate cancers & grade.....	107-108
prostatic intraepithelial neoplasia & reportability.....	12, 96
prostatic intraepithelial neoplasia & single-vs.-multiple primaries.....	21
PSA test & <b>Diagnostic Confirmation</b> .....	121
PSA test <b>CS Site-Specific Factor 1 and 2</b> .....	168D
PUVA.....	207
"questionable" & cancer diagnosis.....	14
<b>Race 1</b> .....	63
<b>Race 2</b> .....	64
<b>Race 3</b> .....	65
<b>Race 4</b> .....	66
<b>Race 5</b> .....	67
race codes.....	8, <u>61-67</u>
radiation, beam.....	189
radiation, boost.....	190
radiation, brachytherapy.....	189, 190
radiation, implants.....	189
radiation, prophylactic .....	189, 190
radiation, radioisotopes .....	189
<b>Radiation / Surgery Sequence</b> .....	193-194
radiation text .....	193
radiation therapy .....	189-194
<b>Radiation Therapy -- Date Started</b> .....	193
<b>Radiation Therapy -- Narrative</b> .....	193
radioactive implants .....	189
radiofrequency ablation.....	178, 189, D-19, D-25, D-46
radioimmunoconjugates .....	191

## INDEX

radioimmunotherapy .....	191
radioisotopes .....	189
radiosensitizers.....	195, 197, 199
radiosurgery .....	178, 189, 190, 191, 192, D-49
<b>Rad--Regional RX Modality</b> .....	190-192
RBA cases & sequence number .....	42-43
<b>Reason For No Primary Site Surgery</b> .....	181-182
<b>Reason for No Surgery (Reason For No Primary Site Surgery)</b> .....	181-182
<b>Record Type</b> .....	218
rectal cancers & single-vs.-multiple primaries.....	18, 22
<b>Recurrence Date--1st</b> .....	9, <u>213</u>
recurrence, reportable & primary site .....	15
<b>Recurrence Type--1st</b> .....	9, <u>213</u> , 218
recurrences & AJCC staging .....	126, 127
recurrences, bladder .....	21
recurrences, first.....	8-10, 15, 21, 24, <u>213</u> , 218
recurrences & PIN III.....	21
recurrences, prostate.....	21
recurrences, reportable .....	2, 8-10, 21
recurrences, reportable & <b>Date of Diagnosis</b> .....	9
recurrences, reportable to the MCR, & sequence number .....	9, 42
recurrences & "same site" .....	21
recurrences, transitional cell carcinomas .....	21
reference books, manuals .....	4-7
reference date, MCR .....	1, 2
<b>Regional Modality</b> .....	190-192
<b>Regional Nodes Examined</b> .....	<u>152-154</u> , 163, 164, 166
<b>Regional Nodes Positive</b> .....	<u>154-156</u> , 163, 164, 166
<b>Registry Code</b> .....	39
<b>Registry ID (Registry Code)</b> .....	39
regulations, MCR.....	1, 2
remarks, text.....	215
renal cancers & grade.....	107
reportability, MCR.....	2, 7-10, <u>11-35</u> , 95-96, 111-113
reportable-by-agreement cases & sequence number .....	42-43
<b>Reporting Facility Code</b> .....	8, 37, <u>38</u> , Appendix G
<b>Reporting Hospital (Reporting Facility Code)</b> .....	8, 37, <u>38</u> , Appendix G
residency (address) rules .....	54-55
residual tumor & AJCC staging .....	126, 127
reticuloendothelial diseases & <b>EOD -- Tumor Size</b> .....	119, 120

## INDEX

reticuloendothelial diseases & <b>Regional Nodes Examined</b> .....	153
reticuloendothelial diseases & <b>Regional Nodes Positive</b> .....	156
reticuloendothelial diseases & scope of regional lymph node surgery .....	183
reticuloendothelial diseases & surgery of other sites .....	185
reticuloendothelial system & primary site .....	80
reticuloendotheliosis, leukemic & primary site .....	79
retinoblastomas & single-vs.-multiple primaries .....	23
retreatment AJCC staging .....	126, 127
retroareolar primary site .....	79
<i>ROADS</i> surgery codes .....	187-188
rTNM .....	126, 127
"rules out" & cancer diagnosis .....	14
<b>RX Coding System--Current (Treatment Coding System--Current)</b> .....	219
<b>RX Date--BRM (Immunotherapy -- Date Started)</b> .....	204
<b>RX Date--Chemo (Chemotherapy -- Date Started)</b> .....	199
<b>RX Date--DX/Stg Proc (Surgical Diagnostic/Staging Procedures -- Date Started)</b> .....	177
<b>RX Date--Hormone (Hormone Therapy -- Date Started)</b> .....	202
<b>RX Date--Most Defin Surg (Date of Most Defin Resection)</b> .....	181
<b>RX Date--Other (Other Therapy -- Date Started)</b> .....	210
<b>RX Date--Radiation (Radiation Therapy -- Date Started)</b> .....	193
<b>RX Date--Surgery (Surgery -- Date Started)</b> .....	180
<b>RX Date--Systemic (Systemic Therapy -- Date Started)</b> .....	194
<b>RX Hosp--BRM (Immunotherapy -- At This Facility)</b> .....	204
<b>RX Hosp--Chemo (Chemotherapy -- At This Facility)</b> .....	199
<b>RX Hosp--DX/Stg Proc (Surgical Diagnostic/Staging Procedures -- At This Facility)</b> .....	177
<b>RX Hosp--Hormone (Hormone Therapy -- At This Facility)</b> .....	201
<b>RX Hosp--Other (Other Therapy -- At This Facility)</b> .....	210
<b>RX Hosp--Palliative Proc (Palliative Care--At This Facility)</b> .....	211
<b>RX Hosp--Scope Reg 98-02 (Scope of Regional Lymph Node Surgery, 1998-2002 -- At This Facility)</b> .....	188
<b>RX Hosp--Scope Reg LN Sur(Scope of Regional Lymph Node Surgery -- At This Facility)</b> .....	185
<b>RX Hosp--Surg Oth 98-02 (Surgery of Other Sites, 1998-2002 -- At This Facility)</b> .....	188
<b>RX Hosp--Surg Oth Reg/Dis (Surgery of Other Sites -- At This Facility)</b> .....	186
<b>RX Hosp--Surg Prim Site (Surgery of Primary Site -- At This Facility)</b> .....	180
<b>RX Hosp--Surg Site 98-02 (Surgery of Primary Site, 1998-2002 -- At This Facility)</b> .....	187

## INDEX

<b>RX Summ--BRM (Immunotherapy -- Summary)</b> .....	204
<b>RX Summ--Chemo (Chemotherapy -- Summary)</b> .....	199
<b>RX Summ--DX/Stg Proc (Surgical Diagnostic/Staging Procedures -- Summary)</b> .....	176
<b>RX Summ--Hormone (Hormone Therapy -- Summary)</b> .....	201
<b>RX Summ--Other (Other Therapy -- Summary)</b> .....	210
<b>RX Summ--Palliative Proc (Palliative Care -- Summary)</b> .....	211
<b>RX Summ--Scope Reg 98-02 (Scope of Regional Lymph Node Surgery, 1998-2002 -- Summary)</b> .....	188
<b>RX Summ--Scope Reg LN Sur (Scope of Regional Lymph Node Surgery -- Summary)</b> .....	185
<b>RX Summ--Surg Oth 98-02 (Surgery of Other Sites, 1998-2002 -- Summary)</b> .....	188
<b>RX Summ--Surg Oth Reg/Dis (Surgery of Other Sites -- Summary)</b> .....	186
<b>RX Summ--Surg Prim Site (Surgery of Primary Site -- Summary)</b> .....	180
<b>RX Summ--Surg/Rad Seq (Radiation / Surgery Sequence)</b> .....	193-194
<b>RX Summ--Surg Site 98-02 (Surgery of Primary Site, 1998-2002 -- Summary)</b> .....	187
<b>RX Summ--Transplnt/Endocr (Hematologic Transplants &amp; Endocrine Procedures)</b> .....	205-206
<b>RX Text--BRM (Immunotherapy -- Narrative)</b> .....	204, 205
<b>RX Text--Chemo (Chemotherapy -- Narrative)</b> .....	199
<b>RX Text--Hormone (Hormone Therapy -- Narrative)</b> .....	202, 205
<b>RX Text--Other (Other Therapy -- Narrative)</b> .....	210
<b>RX Text--Radiation (Beam) (Radiation Therapy -- Narrative)</b> .....	193
<b>RX Text--Surgery (Surgery -- Narrative)</b> .....	181
"same site" & recurrences, reportable .....	21
Sandostatin .....	197, 200, 203, 208
sarcoma & primary site .....	81
sarcoma, Kaposi, & single-vs.-multiple primaries .....	20, 21, 25
sarcoma, myeloid, & primary site .....	79, 89
Satellite, CIMS .....	3, 8, 213, 215, 217
Scarff-Bloom-Richardson grade .....	106-107
scope of regional lymph node surgery .....	182-185
<b>Scope of Regional Lymph Node Surgery -- At This Facility</b> .....	185
scope of regional lymph node surgery & lymphomas.....	183
<b>Scope of Regional Lymph Node Surgery -- Summary</b> .....	185
<b>Scope of Regional Lymph Node Surgery, 1998-2002 -- At This Facility</b> .....	188
<b>Scope of Regional Lymph Node Surgery, 1998-2002 -- Summary</b> .....	188

## INDEX

SEER*Rx Database.....	6, 191, 195-197, 199, 200, 203, 204, 206B, 208, 209
SEER*Rx Database & SEER Book 8 .....	206B
<b>SEER Summary Stage 1977</b> .....	<u>143</u> , 163
<b>SEER Summary Stage 2000</b> .....	<u>144-152</u> , 163
<b>SEER Summary Stage 2000</b> & lung cancers .....	150
<b>SEER Summary Stage 2000</b> & lymphomas .....	145, 150
<b>SEER Summary Stage 2000</b> & timing rule .....	145
<b>SEER Summary Stage 2000</b> & unknown primary site .....	151
Sequence Number .....	8, 9, <u>39-44</u>
<b>Sequence Number--Hospital</b> .....	8, 9, <u>39-44</u>
sequence, radiation/surgery .....	193-194
sequence, systemic treatment/surgery .....	206A
severe dysplasia & reportability .....	14
<b>Sex</b> codes .....	8, <u>60</u>
"simultaneous", single-vs.-multiple primaries .....	20
single-vs.-multiple primaries rules .....	15-33
site-associated morphologies .....	78
site code, primary .....	8, <u>77-81</u>
"site difference", single-vs.-multiple primaries.....	16-18
six-month reporting rule.....	3
size of tumor, EOD .....	<u>116-121</u> , 163
skin cancer reportability exceptions.....	11, 95
smoking codes.....	72
<b>Social Security Number</b> .....	2, 8, <u>53</u>
soft tissue & "site difference" .....	16
software name .....	217
software vendors, relationship with MCR .....	3
<b>Spanish/Hispanic Origin</b> .....	68-72
spouse name .....	76
"spring" & date estimating .....	46, 110, 172
squamous cell carcinomas & reportability exceptions.....	11, 95
"SR" <b>Name Suffix</b> .....	48
stage grouping, clinical .....	<u>133-134</u> , 163
stage grouping, pathologic .....	<u>141-142</u> , 163
staging, collaborative .....	162-167
Staging Narratives.....	157-162
Staging Narratives & lymphomas .....	134, 142
Staging Narratives & multiple tumors in primary site .....	128, 135
Staging Narratives & sites of metastasis .....	132, 140
Staging Narratives & stage-related risk factors .....	133, 141
staging, text .....	161-162

## INDEX

start date, chemotherapy .....	199
start date, hormone therapy .....	202
start date, immunotherapy .....	204
start date, other therapy .....	210
start date, radiation .....	193
start date, systemic therapy .....	194
start dates, treatment (general instructions) .....	171, <u>172</u>
<b>State at Diagnosis</b> .....	57-58
<b>State -- Current</b> .....	59
stent placement & <b>Palliative Care</b> .....	175, 177
stereotactic radiosurgery .....	178, 189, 190, 191, 192, D-49
steroid therapy .....	200-202
storage codes for derived Collaborative Staging fields.....	167-168
<b>Street Address at Diagnosis</b> .....	54, <u>55-56</u>
<b>Street Address at Diagnosis--Supplemental</b> .....	54, 55, <u>56</u>
<b>Street Address -- Current</b> .....	59
<b>Street Address -- Current -- Supplemental</b> .....	59
subareolar primary site.....	79
"suggests" & cancer diagnosis .....	14
Summary Stage 1977 .....	<u>143</u> , 163
Summary Stage 2000 .....	<u>144-152</u> , 163
Summary Stage 2000 & lung cancers .....	150
Summary Stage 2000 & lymphomas.....	145, 150
Summary Stage 2000 & timing rule .....	145
Summary Stage 2000 & unknown primary site .....	151
Summary Stage, <i>in situ</i> terminology .....	148
summary, treatment fields .....	171
"summer" & date estimating .....	46, 110, 172
"supra" & primary site .....	81
surgery.....	177-189
<b>Surgery -- Date Started</b> .....	180
<b>Surgery -- Narrative</b> .....	181
<b>Surgery -- Narrative &amp; surgical diagnostic/staging</b> procedures .....	176, 177
surgery of other sites .....	185-186
<b>Surgery of Other Sites -- At This Facility</b> .....	186
<b>Surgery of Other Sites -- Summary</b> .....	186
<b>Surgery of Other Sites, 1998-2002 -- At This Facility</b> .....	188
<b>Surgery of Other Sites, 1998-2002 -- Summary</b> .....	188
surgery of primary site .....	178-180, 181, Appendix D
<b>Surgery of Primary Site -- At This Facility</b> .....	180
<b>Surgery of Primary Site &amp; chemoembolization</b> .....	195, 207



## INDEX

<b>Surgery of Primary Site -- Summary</b> .....	180
surgery of primary site & lymphomas .....	178
<b>Surgery of Primary Site, 1998-2002 -- At This Facility</b> .....	187
<b>Surgery of Primary Site, 1998-2002 -- Summary</b> .....	187
surgery text.....	181
surgery, lymph node, regional.....	182-185
surgery, regional lymph node.....	182-185
surgery, <i>ROADS</i> codes.....	187-188
surgical diagnostic and staging procedures.....	174-177
<b>Surgical Diagnostic/Staging Procedures -- At This Facility</b> .....	177
<b>Surgical Diagnostic/Staging Procedures -- Date Started</b> .....	177
<b>Surgical Diagnostic/Staging Procedures -- Summary</b> .....	176
"suspected" & cancer diagnosis .....	14
"suspicious" & cancer diagnosis .....	14
Synthroid.....	200
<b>Systemic / Surgery Sequence</b> .....	206A
systemic therapy.....	194-206
<b>Systemic Therapy -- Date Started</b> .....	194
T, clinical .....	<u>128-130</u> , 163
T, pathologic .....	<u>135-137</u> , 163
terms indicating cancer diagnosis .....	13-14
terms indicating <i>in situ</i> behavior.....	97-98
terms indicating <i>in situ</i> Summary Stage.....	148
terms indicating no cancer diagnosis .....	13-14
text, birthplace.....	215
text, chemotherapy .....	199
text, comments / remarks .....	215
<b>Text--DX Proc--Lab Tests</b> .....	160
<b>Text--DX Proc--Op (Text--Operative)</b> .....	160
<b>Text--DX Proc--Path (Text--Pathology)</b> .....	161
<b>Text--DX Proc--PE (Text--Physical Exam)</b> .....	158
<b>Text--DX Proc--Scopes</b> .....	159
<b>Text--DX Proc--X-ray/Scan</b> .....	159
text, hormone .....	<u>202</u> , 205
text, immunotherapy .....	<u>204</u> , 205
<b>Text--Lab Tests</b> .....	160
text, marital status .....	215
<b>Text--Operative</b> .....	160
text, other therapy .....	210
<b>Text--Pathology</b> .....	161
<b>Text--Physical Exam</b> .....	158
text, radiation .....	193

## INDEX

<b>Text--Remarks (Comments / Narrative Remarks)</b> .....	215
<b>Text--Scopes</b> .....	159
<b>Text--Staging</b> .....	161-162
text, tobacco history .....	215
<b>Text--Usual Industry</b> .....	73, 75
<b>Text--Usual Occupation</b> .....	73, 74
<b>Text--X-Ray/Scan</b> .....	159
text, treatment .....	172
Thalidomide .....	207
therapy, other .....	207-210
thyroid cancers & single-vs.-multiple primaries .....	22
thyroid-stimulating hormone.....	200
timing for AJCC staging .....	125
timing for Summary Stage 2000 .....	145
timing rule, reportability .....	3
<b>TNM Clin Descriptor (Clinical Descriptor)</b> .....	127, 163
<b>TNM Clin M (Clinical M)</b> .....	132-133, 163
<b>TNM Clin N (Clinical N)</b> .....	130-131, 163
<b>TNM Clin Stage Group (Clinical Stage Grouping)</b> .....	133-134, 163
<b>TNM Clin T (Clinical T)</b> .....	128-130, 163
<b>TNM Edition Number</b> .....	143, 163
<b>TNM Path Descriptor (Pathologic Descriptor)</b> .....	134-135, 163
<b>TNM Path M (Pathologic M)</b> .....	139-141, 163
<b>TNM Path N (Pathologic N)</b> .....	138-139, 163
<b>TNM Path Stage Group (Pathologic Stage Grouping)</b> .....	141-142, 163
<b>TNM Path T (Pathologic T)</b> .....	135-137, 163
TNM staging .....	123-143, 163
TNM staging & timing rule .....	125
<b>Tobacco History</b> .....	72
tobacco history text .....	215
town at diagnosis.....	57
town, current .....	59
transformation, behavior & single-vs.-multiple primaries .....	26
transfusion, blood.....	208, 209
transient care & reportability .....	12
transitional cell carcinomas & single-vs.-multiple primaries.....	21
transplants, bone marrow .....	205-206
<b>Treatment Coding System -- Current</b> .....	219
treatment narratives.....	172
treatment narratives & estimated start dates (general instruction) .....	172

## INDEX

treatment plan.....	169
treatment start dates (general instructions) .....	171, <u>172</u>
treatment summary fields (general instructions).....	171
treatment text (general instructions).....	172
treatment, at-this-facility (general instructions).....	171
treatment, current, coding system .....	219
treatment, first-course definition.....	169-170
treatment, hormone .....	200-202
treatment, other .....	207-210
treatment, steroid.....	200-202
"tumor" & cancer diagnosis .....	14
tumor markers & Collaborative Staging fields .....	168A-168E
tumor size, EOD.....	<u>116-121</u> , 163
<b>Type of First Recurrence</b> .....	9, <u>213</u> , 218
type of record, NAACCR.....	218
"typical of or for" & cancer diagnosis.....	14
uncertain behavior & grade code .....	104
uncertain behavior & reportability .....	11
unknown primary site.....	79, 86
unknown primary site & AJCC staging .....	124
unknown primary site & <b>EOD -- Tumor Size</b> .....	119, 120
unknown primary site & grade code .....	101
unknown primary site & <b>Laterality</b> .....	82
unknown primary site & <b>Regional Nodes Examined</b> .....	153
unknown primary site & <b>Regional Nodes Positive</b> .....	156
unknown primary site & scope of regional lymph node surgery .....	183
unknown primary site & <b>SEER Summary Stage 2000</b> .....	151
unknown primary site & surgery of other sites .....	185
<b>Usual Industry / Type of Business</b> .....	73, <u>75</u>
<b>Usual Occupation</b> .....	73, <u>74</u>
"usual residence" address.....	54
vaginal intraepithelial neoplasia & reportability.....	12, 95
vaginal intraepithelial neoplasia & sequence number.....	42
VAIN III & reportability.....	12, 13, 95
VAIN III & sequence number.....	42
<b>Vendor Name / Version Number</b> .....	217
vendors, relationship with MCR .....	3
Version 10.....	i, 3
Version 10.1 .....	i, 3
version, NAACCR code.....	218
VIN III & reportability.....	12, 13, 95
VIN III & sequence number.....	42

## INDEX

<b>Vital Status</b> .....	214
vulvar intraepithelial neoplasia & reportability .....	12, 95
vulvar intraepithelial neoplasia & sequence number .....	42
WHO grade & CNS tumors .....	104
WHO grade & ICD-O grade .....	104
Wilms tumors & single-vs.-multiple primaries.....	23
"winter" & date estimating.....	46, 110, 172
work history .....	73-75
"worrisome" & cancer diagnosis.....	14
yTNM.....	125, 126
Zevalin .....	191, 203, 206B
ZIP Codes, Massachusetts .....	Appendix F
<b>ZIP / Postal Code at Diagnosis</b> .....	59
<b>ZIP / Postal Code -- Current</b> .....	59